Opinion|Videos|March 5, 2025
Management of GI AEs with ALK Inhibitors
Key opinion leaders examine how to manage gastrointestinal side effects in patients on lorlatinib, including preventive tips and comparisons with GI management strategies for other ALK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you manage gastrointestinal side effects in patients on lorlatinib?
- Do you provide any preventive tips, and how does this compare to managing GI side effects from other ALK inhibitors?
Advertisement
Related to this article
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
The FDA has approved oral iberdomide (Zenbexus) for relapsed/refractory multiple myeloma, offering patients a highly potent, accessible therapy.
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
With daraxonrasib approved for metastatic pancreatic cancer, Yolanda Justal, APRN, discusses essential nursing workflows for home-based care.
Beth Sandy, CRNP, of Penn Medicine explains how oncology nurses and pharmacists collaborate to manage financial toxicity and secure oral therapies.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Palliative and Psycho-Oncology Care: Dr. Ramy Sedhom on Patient Distress Signs
2
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer
3
WCLC 2026: Oncology Nursing Takeaways on Supportive Care and APP-Led Models
4
Recognizing and Evaluating Diarrhea in Metastatic Triple-Negative Breast Cancer
5